CEO Prashant Kohli Buys $214K of GRCE Stock at $2.14
GRCE sits 16% above its 52-week low of $1.79.
Summary
CEO Prashant Kohli bought 100,000 shares of Grace Therapeutics for $214,000 at $2.14 per share, increasing his direct holdings to 121,357 shares.
Key Events · Ownership and Investor Activity · GRCE
-
CEO Buys $214K of Stock
Prashant Kohli purchased 100,000 shares at $2.14 per share for $214,000 on September 9, 2026, raising his direct holdings to 121,357 shares.
-
Open-Market Purchase, Not Compensation
The transaction is coded as an open-market purchase (P), not an option exercise or grant, indicating real cash outlay by the CEO.
-
Purchase Above Recent Placement Price
The $2.14 purchase price is slightly above the $2.10 per share private placement completed in August 2026, suggesting confidence in the company's valuation.
-
Context: FDA Resubmission Path
The purchase follows FDA Type A meeting minutes confirming no clinical issues with GTx-104 and a clear resubmission path, as disclosed in July 2026.
Analysis · GRCE · Life Sciences
CEO Prashant Kohli bought 100,000 shares at $2.14 per share for $214,000 on September 9, 2026, raising his direct stake to 121,357 shares. This is a real-money open-market purchase, not an option exercise or grant, and it comes just weeks after the company raised $10 million in a private placement at $2.10 per share and filed an S-3 to register those shares for resale. The CEO's willingness to buy at $2.14 — slightly above the recent placement price — is a notable show of conviction while the company works through the FDA resubmission path for GTx-104.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRCE was trading at $2.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.